Why Grade 3 and 4 cartilage damage does not heal on its own

Being told you have Grade 3 or Grade 4 cartilage damage raises an immediate question: what does that grade actually mean, and why won't it settle down with rest?

The grading comes from the International Cartilage Repair Society (ICRS) classification, which describes defect depth rather than symptom severity. A Grade 3 lesion extends more than 50% of the way through the cartilage — in some subtypes (3C and 3D) reaching through the calcified layer just above the subchondral bone, without yet breaking through it. Grade 4 goes further: the cartilage is lost in full thickness and the underlying bone is directly exposed to the joint space.

The reason neither grade heals naturally lies in cartilage biology. Articular cartilage — the smooth, load-bearing lining inside the knee — has no blood vessels and no nerve fibres. That unusual structure is what allows it to function silently as a frictionless surface for decades, but it also means that when a focal defect forms, no blood-borne progenitor cells or repair signals can reach it. The damage simply persists.

Left without structural intervention, a focal chondral hole tends either to remain as a bare-bone area or to fill gradually with fibrous tissue — a mechanically weaker substitute that accelerates deterioration of the surrounding joint surface.

Grade 3 and 4 lesions occupy a distinct clinical position: severe enough to impair function and cause pain, yet the joint is not bone-on-bone throughout. That distinction matters, because joint-preservation options remain realistic at these grades — in contrast to end-stage osteoarthritis, where replacement is usually the primary conversation. MRI is the standard tool for mapping defect depth, area, and location before any treatment decision is made.

How ChondroFiller works as an injectable collagen scaffold

Once a focal defect is confirmed on MRI, the practical question becomes how to give it the structural conditions it cannot create for itself. ChondroFiller® is a CE-marked Class III medical device — an acellular, injectable Type I collagen hydrogel — designed to do exactly that. Supplied in a ready-to-use two-chamber syringe, it requires no biopsy, no cell culture, and no bone drilling: the collagen and neutralising solution mix at the tip during injection and polymerise in situ within approximately 3–5 minutes, conforming precisely to the geometry of the defect.

The mechanism is acellular matrix-induced chondrogenesis. Once the gel has set, it acts as a three-dimensional collagen template — a temporary internal framework — that progenitor cells from the surrounding synovium and subchondral bone can migrate into and organise around. An ex vivo osteochondral model confirmed a 2.4-fold increase in DNA content within ChondroFiller-filled defects by day 14, providing direct evidence of cell migration into the scaffold. The collagen matrix degrades gradually as the recruited cells produce repair tissue; the scaffold is temporary by design, intended to support the body's own repair processes rather than to substitute for them permanently.

This places ChondroFiller in a distinct category from other injectable options. Hyaluronic acid improves joint lubrication but provides no physical structure within a defect. Polyacrylamide hydrogels such as Arthrosamid occupy space as a long-term filler without generating a cell-recruitment matrix. ChondroFiller is neither of those: it is a regenerative scaffold that promotes endogenous repair through acellular matrix-induced chondrogenesis, then retreats as new tissue matures.

Who is a suitable candidate

Several factors point towards ChondroFiller being a reasonable option — and an honest look at the exclusions is just as useful as the inclusion list.

Inclusion signals

The central requirement is a focal cartilage defect: a clearly delineated lesion on MRI rather than widespread thinning across multiple compartments. Grade 3 and Grade 4 ICRS lesions in the knee are the primary indication. Defects of 3 cm² or more are considered particularly suited to matrix-based repair, where a structural scaffold can address the full area more reliably than microfracture techniques alone.

Patients who arrive at this point have typically not found adequate relief through conservative management — structured physiotherapy, load modification, and analgesics. That prior pathway is a reasonable signal that something structural needs to be addressed.

Age is not a hard barrier. Clinical guidance does not set an upper age limit; biological age, activity goals, and defect characteristics carry more weight than the year on a birth certificate.

Factors that reduce suitability

Generalised bone-on-bone osteoarthritis throughout the joint is not an indication — ChondroFiller addresses focal loss, not diffuse end-stage disease. Significant malalignment of the knee that has not been corrected, and very large or multi-compartment disease, also reduce expected benefit.

Distinguishing focal from generalised damage requires careful imaging assessment. onMRI™ AI-driven cartilage MRI analysis — available through Lincolnshire Knee — can support that evaluation by mapping defect depth and area with precision. Ultimately, a consultant-led review is needed to confirm suitability; knee pain alone does not establish a patient as a candidate.

What the injection procedure involves

Arriving at the clinic, most patients are surprised by how straightforward the appointment is. The entire procedure — from preparation through to discharge — is typically completed within 30 to 45 minutes, with no theatre admission, no general anaesthetic, and no incision required.

The clinician uses ultrasound imaging throughout to guide the needle precisely to the focal defect, ensuring the collagen solution is placed accurately rather than dispersed into the broader joint space. Once the syringe's two chambers combine at the tip during injection, the collagen matrix begins polymerising within the defect over approximately 3–5 minutes — setting into a dimensionally stable gel scaffold that conforms to the lesion's shape. The ultrasound guidance is what makes that accuracy possible in an outpatient setting.

After the injection, patients are discharged the same day. Instructions will include a period of restricted weight-bearing — typically around six weeks — to allow cells from the surrounding synovium and subchondral bone to migrate into the scaffold before it is exposed to full joint loading. Biomechanical evidence suggests that early unrestricted loading before stable defect filling is achieved can compromise the initial integration of the material, which is why this phase of the recovery plan matters.

Recovery timeline and what results to expect

The six-week restricted weight-bearing phase described at the end of your appointment is not arbitrary caution — it is the period during which the scaffold is most vulnerable to displacement before host cells have consolidated within it. Once that window closes, rehabilitation moves through progressive stages: early range-of-motion work to prevent joint stiffness, followed by graduated strengthening exercises, and eventually a return to fuller activity over the subsequent months. The exact pace depends on defect size, location, and individual response, and should be guided by the treating consultant and physiotherapist.

What published outcome data show

In a controlled, randomised multicentre study comparing ChondroFiller liquid with microfracture for focal knee cartilage defects (23 patients), the ChondroFiller group showed statistically significant IKDC score improvements at three and six months, sustained through to 12 months, with no adverse events reported. MRI assessment using the MOCART scoring system — which evaluates how well the repair tissue fills and integrates within the defect — demonstrated values in the range of 70–87, indicating good to complete lesion filling. A separate prospective series of 17 patients treated arthroscopically with ChondroFiller gel found significant improvement in both the Lysholm scale and IKDC at three, six, and 12 months (p<0.05), with scores stabilising between six and 12 months. Across the available knee outcome data, IKDC improvement of approximately 30 points over 12 months is reported — a difference generally considered clinically meaningful in patient-reported knee function.

These findings come from studies of modest size, and they should be understood as evidence of consistent directional benefit rather than a guarantee of any individual result.

Longer-term durability

For the injectable delivery route specifically, robust long-term follow-up data beyond five years have not yet been published. This is a genuine evidence gap, not a complication signal — the injectable pathway is relatively newer than the arthroscopic approach, and outcome registries are still accumulating. Patients should factor this into their decision-making alongside the favourable medium-term picture that does exist.

Getting assessed at Lincolnshire Knee

For patients in Lincolnshire and the surrounding area, a consultant-led assessment at Lincolnshire Knee is the practical starting point. Clinics run at Sleaford NG34 and Grantham NG31, and no GP referral is needed to book. A first appointment typically involves a clinical examination, a review of any existing scan findings, and — where the picture is not yet clear — onward MRI to characterise whether the defect is focal, what grade it represents, and whether the surrounding joint is suitable for a scaffold approach. Suitability for ChondroFiller injection is established through that assessment process, not assumed beforehand; the same consultation can also explore whether a broader management plan makes more sense for a given patient.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.

1. [1] Ultramodern natural and synthetic polymer hydrogel scaffolds for articular cartilage repair and regeneration. (2025). https://doi.org/10.1186/s12938-025-01342-3 https://doi.org/10.1186/s12938-025-01342-3